The mechanism of glomerular infiltration of monocytes remains unknown in diabetic nephropathy. We examined the effect of a high glucose concentration on monocyte chemotactic peptide 1 (MCP-1) expression in human mesangial cells (MCs) by using enzyme-linked immunosorbent assay and reverse transcription coupled with polymerase chain reaction (PCR). More than a 50% increase in the MCP-1 protein production was observed in MCs cultured in high-glucose medium (450 mg/dl) as compared to normal glucose (100 mg/dl; 1,496 ± 75 vs. 966 ± 15 pg/ml after 24 h, 1,910 ± 93 vs. 1,250 ± 55 pg/ml after 48 h). Semiquantitative PCR showed that phorbol myristate acetate (100 nM) increased the ratio of PCR products for MCP-1 to housekeeping gene glyceraldehyde-3-phosphate dehydrogenase on densitometric results at 24 h by 2.7-fold, which was prevented by calphostin C (200 nM) pretreatment. High glucose increased the ratio by 3-fold as compared to normal glucose at 24 h (0.72 ± 0.11 vs. 0.24 ± 0.01). This was also suppressed by calphostin C pretreatment. These findings demonstrate that high glucose can directly increase MCP-1 expression in MCs, which may contribute to monocyte infiltration in diabetic nephropathy, and this is regulated by protein kinase C.

Keywords:
Monocyte chemotactic peptide 1, High-glucose medium, Mesangial cells, Protein kinase C
1.
Cattell V: Macrophages in acute glomerular inflammation. Kidney Int 1994;45:945–952.
2.
Magil A, Cohen AH: Monocytes and focal glomerulosclerosis. Lab Invest 1989;61:404–409.
3.
Floege J, Alpers CE, Burns MW, Pritzl P, Gordon K, Couser WG, Johnson RJ: Glomerular cells, extracellular matrix accumulation, and the development of glomerulosclerosis in the remnant kidney model. Lab Invest 1992;66:485–497.
4.
Klahr S, Schreiner G, Ichikawa I: The progression of renal disease. N Engl J Med 1988;318:1657–1666.
5.
Furuta T, Saito T, Ootaka T, Soma J, Obara K, Abe K, Yoshinaga K: The role of macrophages in diabetic glomerulosclerosis. Am J Kidney Dis 1993;21:480–485.
6.
Young BA, Johnson RJ, Alpers CE, Eng E, Gordon K, Floege J, Couser WG: Cellular events in the evolution of experimental diabetic nephropathy. Kidney Int 1995;47:935–944.
7.
Eng E, Floege J, Young BA, Couser WG, Johnson RJ: Does extracellular matrix expansion in glomerular disease require mesangial cell proliferation. Kidney Int 1994;45(suppl 45):45–47.
8.
Wahl SM, Hunt DA, Wakefield LM, McCartney-Francis N, Wahl LM, Roberts AB, Sporn MB: Transforming growth factor beta (TGFβ) induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987;84:5788–5792.
9.
Skolnik EY, Yang Z, Makita Z, Radoff S, Kirstein M, Vlassara H: Human and rat mesangial cell receptors for glucose-modified proteins: Potential role in kidney tissue remodelling and diabetic nephropathy. J Exp Med 1991;174:931–939.
10.
Stewart J, Weir DM: Carbohydrates as recognition molecules in macrophage activities. J Clin Lab Immunol 1989;28:103–108.
11.
Weiser WY, Greieder DK, Remold HG, David JR: Studies on human migration inhibitory factor: Characterization of three molecular species. J Immunol 1981;126:1958–1963.
12.
Rollins BJ, Yoshimura T, Leonard EJ, Prober SJ: Cytokine-activated human endothelial cells synthesize and secrete a monochemoattractant, MCP-1/JE. Am J Pathol 1990;136:1229–1233.
13.
Wenzel UO, Abboud HE: Chemokines and renal disease. Am J Kidney Dis 1995;26:982–994.
14.
Schloendorff D, Nelson PJ, Luckow B, Banas B: Chemokines and renal disease. Kidney Int 1997;51:610–621.
15.
Rovin BH, Tan LC: Role of protein kinase pathways in IL-1 induced chemoattractant expression by human mesangial cells. Kidney Int 1994;46:1059–1068.
16.
Colotta F, Borre A, Wang JM, Tattanelli M, Maddalena F, Polentarutti N, Peri G, Matovani A: Expression of a monocyte chemotactic cytokine by human mononuclear phagocytes. J Immunol 1992;148:760–765.
17.
Stahl RAK, Thaiss F, Disser M, Helmch U, Hora K, Schloendorff D: Increased expression of monocyte chemoattractant protein-1 in anti-thymocyte antibody induced glomerulonephritis. Kidney Int 1993;44:1036–1047.
18.
Rovin BH, Rumancik M, Tan L, Dickerson J: Glomerular expression of monocyte chemoattractant protein-1 in experimental and human glomerulonephritis. Lab Invest 1994;71:536–542.
19.
Tang WW, Yin SM, Wittwer AJ, Oi MY: Chemokine gene expression in anti-glomerular basement membrane antibody glomerulonephritis. Am J Physiol 1995;269:F323–F330.
20.
Park IS, Kiyomoto H, Barnes JL, Woodruff K, Abboud HE: Glomerular monocyte infiltration in early streptozotocin-induced diabetes is associated with increased expression of transforming growth factor and cellular fibronectin (abstract). J Am Soc Nephrol 1994;5:971.
21.
Rovin BH, Doe N, Tan LC: Monocyte chemoattractant protein-1 levels in patients with glomerular disease. Am J Kidney Dis 1996;27:640–646.
22.
Ayo SH, Radnik R, Garoni J, Troyer DA, Kreisberg JI: High glucose increases diacylglycerol mass and activates protein kinase C in mesangial cell cultures. Am J Physiol 1991;261:F571–F577.
23.
Ayo SH, Radnik RA, Glass WF II, Garoni JA, Rampt ER, Appling DR, Kreisberg JI: Increased extracellular matrix synthesis and mRNA in mesangial cells grown in high-glucose medium. Am J Physiol 1991;260:F185–F191.
24.
Ihm CG, Park JK, Ahn JH, Lee TW, Cho BS, Kim MJ: Effect of glucose and cytokines on the expression of cell adhesion molecules on mesangial cells. Kidney Int 1995;48(suppl 51):39–42.
25.
Nahman NS, Leonhart KL, Cosio FG, Hebert CL: Effects of high glucose on cellular proliferation and fibronectin production by cultured human mesangial cells. Kidney Int 1992;41:396–402.
26.
Wolf G, Sharma K, Chen Y, Ericksen M, Ziyadeh FN: High glucose-induced proliferation in mesangial cells is reversed by autocrine TGF-β. Kidney Int 1992;42:647–656.
27.
Kakizaki Y, Waga S, Sugimoto K, Tanaka H, Nukii K, Takeya M, Yoshimura T, Yokoyama M: Production of monocyte chemoattractant protein-1 by bovine glomerular endothelial cells. Kidney Int 1995;48:1866–1874.
28.
Striker GE, Striker LJ: Glomerular cell culture. Lab Invest 1985;53:122–131.
29.
Border WA, Okuda S, Languino LR, Ruoslahti E: Transforming growth factor-β regulates production of proteoglycans by mesangial cells. Kidney Int 1990;37:689–695.
30.
Moriyama T, Murphy HR, Martin BM, Perez G: Detection of specific mRNAs in single nephron segments by use of the polymerase chain reaction. Am J Physiol 1990;258:F1470–F1474.
31.
Kaneto H, Morrissey J, Klahr S: Increased expression of TGF-β mRNA in the obstructed kidney of rats with unilateral ureteral ligation. Kidney Int 1993;44:313–321.
32.
Furutani Y, Nomura H, Notake M, Oyamada Y, Fukui T, Yamada M, Larsen CG, Oppenheim JJ, Matsushima K: Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF). Biochem Biophys Res Commun 1989;159:249–255.
33.
Ercolani L, Florence B, Denaro M, Alexander M: Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J Biol Chem 1988;263:15335–15341.
34.
Ha HJ, Yoon SJ, Kim KH: High glucose can induce lipid peroxidation in the isolated rat glomeruli. Kidney Int 1994;46:1620–1626.
35.
Satriano J, Schloendorff D: Activation and attenuation of transcription factor NF-kB in mouse glomerular mesangial cells in response to tumor necrosis factor-alpha, immunoglobulin G, and adenosine 3′:5′-cyclic monophosphate. Evidence for involvement of reactive oxygen species. J Clin Invest 1994;94:1629–1636.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.